ASCO 2022 Conference Coverage
Avatar

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet

By ASCO 2022 Conference Coverage FEATURING Claudio Cerchione
June 8, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights 2023: State of the Art and Next Questions

Wed, Nov 1, 2023
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel
07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
44:49
Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

Feat. K. Anderson
05:22
PrecisCa

Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Tri…

Feat. A. Nooka
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
15:08
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient

New Therapies for Relapsed Myeloma in 2023

Feat. D. Vogl
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
30:59
Houston Methodist Hospital

Overview of Advances in Multiple Myeloma

Feat. S. Ganguly
15:54
Paul Richardson

Emerging Strategies in the Management of Relapsed MM

11:20
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "First Phase 3 Results From CARTITUDE-4 - …

Feat. B. Dhakal
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
20:50
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Multiple Roadblocks to Access for CAR-T in MM: Optimizing Road C…

Feat. K. Patel
20:11
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Combination Therapy Trials in Myeloma - A …

Feat. A. Jakubowiak
34:48
Kenneth Anderson

MM Cured in 2030 - What Are the Next Steps?

Feat. K. Anderson
04:17
ecancer

ASCO® 2023 Insights: "CARTITUDE-4 Study Summary - Cilta-Cel Vs.…

Feat. B. Dhakal